SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-032638
Filing Date
2022-02-09
Accepted
2022-02-09 16:01:59
Documents
14
Period of Report
2022-02-09
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d303532d8k.htm   iXBRL 8-K 30333
2 EX-10.1 d303532dex101.htm EX-10.1 63608
3 EX-99.1 d303532dex991.htm EX-99.1 11915
  Complete submission text file 0001193125-22-032638.txt   258250

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA cmpi-20220209.xsd EX-101.SCH 2882
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE cmpi-20220209_lab.xml EX-101.LAB 18739
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cmpi-20220209_pre.xml EX-101.PRE 11725
8 EXTRACTED XBRL INSTANCE DOCUMENT d303532d8k_htm.xml XML 3465
Mailing Address 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142
Business Address 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142 978-503-2124
Checkmate Pharmaceuticals, Inc. (Filer) CIK: 0001651431 (see all company filings)

IRS No.: 364813934 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39425 | Film No.: 22607134
SIC: 2836 Biological Products, (No Diagnostic Substances)